Can testosterone replacement decrease the memory problem of old age?

Medical Hypotheses

Volumn 60, Issue 6, 2003, Pages 893-896

  Lim, David ^a,b   Flicker, Leon ^a   Dharamarajan, Arunasalam ^a   Martins, Ralph N ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b NONE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; ANDROGEN; ANDROGEN RECEPTOR; APOLIPOPROTEIN A1; APOLIPOPROTEIN C2; APOLIPOPROTEIN E; CHOLESTEROL; CYTOKINE; ESTROGEN; FATTY ACID; NITRIC OXIDE; POTASSIUM CHANNEL; TAU PROTEIN; TESTOSTERONE;

AGING; ALZHEIMER DISEASE; CLINICAL TRIAL; DEMENTIA; FEMALE; GENE; HEALTH CARE COST; HORMONE SUBSTITUTION; HUMAN; INCIDENCE; LIPID METABOLISM; MALE; MEMORY DISORDER; NERVE DEGENERATION; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; VASCULAR SMOOTH MUSCLE; X CHROMOSOME;

EID: 0037410541     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-9877(03)00072-0     Document Type: Review

References (62)

1. Tenover J. L. Testosterone and the aging male. J Androl 1997; 18: 103-106.
2. Tenover J. L. Male hormone replacement therapy including andropause. Gonadal Disord 1998; 27: 969-987.
3. Seidman S. N., Rabkin J. G. Testosterone replacement therapy for hypogonadal men with SSRI-refractory depression. J Affect Disord 1998; 48: 157-161.
4. Stembach H. Age-associated testosterone decline in men: clinical issues for psychiatry. Am J Psychiatry 1998; 155: 1310-1318.
5. Fillit H. et al. Observations in a preliminary open trial of estradiol therapy for senile dementia: Alzheimer's type. Psychoneuroendocrinology 1986; 11: 337-345.
6. Ohkura T. et al. Long-term estrogen replacement therapy in female patients with dementia of the Alzheimer type: 7 case reports. Dementia 1995; 6: 99-107.
7. Birge S. J., Mortel K. F. Estrogen and the treatment of Alzheimer's disease. Am J Med 1997; 103: 36S-45S.
8. Simpkins J. W. et al. Role of estrogen replacement therapy in memory enhancement and the prevention of neuronal loss associated with Alzheimer's disease. Am J Med 1997; 103: 19S-25S.
9. Schneider L. S., Farlow M. R., Pogoda J. M. Potential role of estrogen replacement therapy in the treatment of Alzheimer's dementia. Am J Med 1997; 103: 46S-50S.
10. Henderson V. W. The epidemiology of estrogen replacement therapy and Alzheimer's disease. Neurology 1997; 48: S27-S35.
11. Kawas C. et al. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: the Baltimore Longitudinal Study of Aging. Neurology 1997; 48: 1517-1521.
12. Teter B., Harris-White M. E., Frautschy S. A., Cole G. M. Role of apolipoprotein E and estrogen in mossy fibre sprouting in hippocampal slice cultures. Neuroscience 1999; 91: 1009-1016.
13. Toran-Allerand C. D. et al. Estrogen receptors colocalize with low affinity nerve growth factor receptors in cholinergic neurons of the basal forebrain. Proc Natl Acad Sci USA 1992; 89: 4668-4672.
14. Urabe M. et al. Effect of estrogen replacement therapy on hepatic triglyceride lipase, lipoprotein lipase and lipids including apolipoprotein E in climacteric and elderly women. Endocrinology 1996; 43: 737-742.
15. Maki P. M., Resnick S. M. Longitudinal effects of estrogen replacement therapy on PET cerebral blood flow and cognition. Neurobiol Aging 2000; 21: 373-383.
16. Ray P., Ghosh S. K., Zhang D. H., Ray A. Repression of interleukin-6 gene expression by 17β-estradiol: inhibition of the DNA-binding activity of the transcription factors NF-IL6 and NF-κB by the estrogen receptor. FEBS Lett 1997; 409: 79-85.
17. Bae Y. H., Hwang J. Y., Kim Y. H., Koh J. Y. Anti-oxidative neuroprotection by estrogens in mouse cortical cultures. J Korean Med Sci 2000; 15: 327-336.
18. Manthey D., Heck S., Behl C. The female sex hormone estrogen induces and increased release ofsoluble non-amyloidogenic β-amyloid precursor protein (sAPP) via the activation of mitogen-activated-protein-kinase (MAPKinase) and phosphokinase C (PKC). Neurobiol Aging 2000; S1.
19. Petanceska S. S., Nagy V., Frail D., Gandy S. Ovariectomy and 17β-estradiol modulate the levels of Alzheimer's amyloid-β peptides in brain. Neurology 2000; 54: 2212-2217.
20. Moffat S. D., Hampson E. A curvilinear relationship between testosterone and spatial cognition in humans: possible influence of hand preference. Psychoneuroendocrinology 1996; 21: 323-337.
21. Almeida O. P., Barclay L. Sex hormones and their impact on dementia and depression: a clinical perspective. Expert Opin Pharmacother 2001; 2: 527-535.
22. Papsozomenos S. C. The heat shock-induced hyperphosphorylation of θ is estrogen-independent and prevented by androgens: implications for Alzheimer's disease. Proc Natl Acad Sci USA 1997; 94: 6612-6617.
23. Gouras G. K. et al. Testosterone reduces neuronal secretion of Alzheimer's β-amyloid peptides. Proc Natl Acad Sci USA 2000; 97: 1202-1205.
24. Tirassa P. et al. High-dose anabolic steroids modulate concentration of nerve-growth factor and expression of its low affinity receptor (p75-NGFr) in male rat brain. J Neurosci Res 1997; 47: 198-207.
25. Day J. R., Frank A. T., O'Callaghan J. P., Jones B. C., Anderson J. E. The effect of age and testosterone on the expression of glial fibrillary acidic protein in the rat cerebellum. Exp Neurol 1998; 151: 343-346.
26. Jones K. J., Storer P. D., Drengler S. M., Oblinger M. M. Differential regulation of cytoskeletal gene expression in hamster facial motoneurons: effects of axotomy and testosterone treatment. J Neurosci Res 1999; 57: 817-823.
27. Lustig R. H., Hua P., Smith L. S., Wang C., Chang C. An in vitro model for the effects of androgen on neurons employing androgen receptor-transfected PC12 cells. Mol Cell Neurosci 1994; 5: 587-596.
28. Yoshizawa A., Clemmons D. R. Testosterone and insulin-like growth factor (IGF) I interact in controlling IGF-binding protein production in androgen-responsive forsekin fibroblast. J Clin Endocrinol Metab 2000; 85: 1627-1633.
29. Wozniak A., Hutchison R. E., Morris C. M., Hutchison J. B. Neuroblastoma and Alzheimer's disease brain cells contain aromatase activity. Steroids 1998; 63: 263-267.
30. Lue Y. H. et al. Single exposure to heat induces stage-specific germ cell apoptosis in rats: role on intratesticular testosterone on stage specificity. Endocrinology 1999; 141: 1709-1717.
31. Smale G., Nicholas N. R., Brady D. R., Finch C. E., Horton J. W. E. Evidence for apoptotic cell death in Alzheimer's disease. Exp Neurol 1995; 133: 225-230.
32. Hammond J. et al. Testosterone-mediated neuroprotective through the androgen receptor in human primary neurons. J Neurochem 2001; 77: 1319-1326.
33. Frye C. A., McCormick C. M. Androgens are neuroprotective in the dentate gyrus of adrenalectomized female rats. Stress 2000; 3: 185-194.
34. Pike C. J. Testosterone attenuates β-amyloid toxicity in cultured hippocampal neurons. Brain Res 2001; 919: 160-165.
35. Gandy S. et al. Chemical andropause and amyloid-β peptide. J Am Med Assoc 2001; 285: 2195-2196.
36. Almeida O. P. et al. Effect of testosterone deprivation on the cognitive performance of a patient with Alzheimer's disease. Int J Psychiatry 2001; 16: 822-825.
37. Hogervorst E. et al. Serum total testosterone is lower in men with Alzheimer's disease. Neuroendocrinol Lett 2001; 22: 163-168.
38. Brinkmann A. O. In: 11th International Congress of Endocrinology. Sydney: Pharmacia, 2000.
39. Tohgi H., Utsugisawa K., Yamagata M., Yoshimura M. Effects of age on messenger RNA expression of glucocorticoid, thyroid hormone, androgen, and estrogen receptors in postmortem human hippocampus. Brain Res 1995; 700: 245-253.
40. Sharp A., Robinson D., Jacobs P. Age- and tissue-specific variation of X chromosome inactivation ratios in normal women. Hum Genet 2000; 107: 343-349.
41. Di Lorio A., Zito M., Lupinetti M., Abate G. Are vascular factors involved in Alzheimer's disease? Facts and theories. Aging Clin Exp Res 1999; 11: 345-352.
42. Alexandersen P., Haarbo J., Byrjalsen I., Lawaetz H., Christiansen C. Natural androgens inhibit male arteriosclerosis: a study in castrated, cholesterol-fed rabbits. Circ Res 1999; 84: 813-819.
43. Zgliczynski S. et al. Effect of testosterone replacement therapy on lipids and lipoproteins in hypogonadal and elderly men. Arteriosclerosis 1996; 121: 35-43.
44. Krenzer K. L. et al. Effect of androgen deficiency on the human meibomian gland and ocular surface. J Clin Endocrinol Metab 2000; 85: 4874-4882.
45. Tam S. P., Archer T. K., Deeley R. G. Biphasic effects of estrogen on apolipoprotein synthesis in human hepatoma cells: mechanism of antagonism by testosterone. Proc Natl Acad Sci USA 1986; 83: 3111-3115.
46. Whiting K. P., Restall C. J., Brain P. F. Steroid hormone-induced effects on membrane fluidity and their potential roles in non-genomic mechanisms. Life Sci 2000; 67: 743-757.
47. English K. M. et al. Men with coronary artery disease have lower levels of androgens than men with normal coronary angiograms. Eur Heart J 2000; 21: 890-894.
48. Rolf C., Nieschlag E. Potential adverse effects of long-term testosterone therapy. Bailliere's Clin Endocrinol Metab 1998; 12: 521-534.
49. Pandey K. N., Oliver P. M., Maeda N., Smithies O. Hypertension associated with decreased testosterone levels in natriuretic peptide receptor-A-gene-knockout and gene-duplicated mutant mouse models. Endocrinology 1999; 140: 5112-5119.
50. Nasman B. et al. Serum dehydroepiandrosterone sulfate in Alzheimer's disease and multi-infarct dementia. Biol Psychiatry 1991; 30: 684-690.
51. Azuman T. et al. The effect of dehydroepiandrosterone sulfate administration to patients with multi-farct dementia. J Neurol Sci 1999; 162: 69-73.
52. Sih R. et al. Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J Clin Endocrinol Metab 1997; 82: 1661-1667.
53. Webb C. M., Adamson D. L., De Zeigler D., Collins P. Effect of acute testosterone on myocardial ischemia in men with coronary artery disease. Annu J Cardiol 1999; 83: 437-439.
54. Goudsmit E., Filets E., Swaab D. F. Changes in vasopression neurons and fibers in aging and Alzheimer's disease: reversibility in the rat. Alzheimer's Dis Relat Disord 1989; 317: 1193-1208.
55. Geary G. C., Krause D. N., Duckles S. P. Gonadal hormones affect diameter of male rat cerebral arteries through endothelium-dependent mechanism. Am J Heart Circ Physiol 2000; 279: 610-618.
56. Franck-Lissbrant I., Haggstrom S., Damber J. E., Bergh A. Testosterone stimulates angiogenesis and vascular regrowth in the ventral prostate in castrated adult rats. Endocrinology 1998; 139: 451-456.
57. Cignarella A. et al. Androgen deprivation, estrogen treatment and vascular function in male rat aorta. Naunyn-Schmiedeberg's Arch Pharmacol 2000; 361: 166-172.
58. Weiler P. G., Lubberm J. E., Chi I. Cognitive impairment and hospital use. Am J Public Health 1991; 81: 1153-1157.
59. Shapiro E., Tate R. B. The impact of a mental status score and a dementia diagnosis on mortality and institutionalization. J Ageing Health 1991; 3: 28-46.
60. Callahan C. M., Hendrie H. C., Tierney W. M. Documentation and evaluation of cognitive impairment in elderly primary care patients. Annu Int Med 1995; 122: 422-429.
61. Ernst R. L., Hay J. W. The US economic and social costs of Alzheimer's disease revisited. Am J Public Health 1994; 84: 1261-1264.
62. Taylor D. H. J., Schenkman M., Zhou J., Sloan F. A. The relative effect of Alzheimer's disease and related dementias, disability, and comorbidities on cost of care for elderly person. J Gerontol 2001; 56: S285-S293.